Try our Advanced Search for more refined results
Health
-
January 05, 2026
Cancer Biotech Co. Eyes $182M IPO
A company developing new drugs for treating cancer disclosed Monday it is looking to raise roughly $182 million in an initial public offering guided by Paul Hastings LLP and Davis Polk & Wardwell LLP, teeing it up for the first major IPO of 2026.
-
January 05, 2026
Aetna Drug Price-Fixing Suit Against Pharma Cos. Paused
A judge has paused Aetna Inc.'s Connecticut Superior Court lawsuit accusing nearly two dozen pharmaceutical companies of fixing the prices of generic drugs, refusing drugmakers' bids to dismiss the case but agreeing to put it on hold pending the outcomes of similar cases in other jurisdictions.
-
January 05, 2026
Health Officials Roll Back Child Vaccine Recommendations
Amid public outcry, federal health officials on Monday revised vaccine recommendations for American children, cutting the number from 18 to 11 and bringing the United States in line with other developed countries such as Denmark.
-
January 05, 2026
Calif. Tribe Sues IHS Over Opioid Center Compact Denial
A California tribe is asking a federal court to order the Indian Health Service to approve a proposed agreement for an opioid treatment center, arguing that the funding is desperately needed after multiple tragedies due to drug addiction in and outside its reservation.
-
January 05, 2026
Simpson Thacher Opens San Francisco Office
Simpson Thacher & Bartlett LLP is expanding its California presence, announcing Monday it has opened an office in San Francisco.
-
January 05, 2026
Ind. Sues Eli Lilly Over 'Grossly Inflated' Insulin Prices
Indiana's attorney general on Monday announced a state court suit against Eli Lilly alleging it schemed to artificially inflate the price of insulin, saying the litigation follows two years of ultimately unsuccessful attempts to resolve the matter without litigation against the drug manufacturer.
-
January 05, 2026
DOL Names Acting Benefits Official For EBSA Operations
The U.S. Department of Labor has appointed a senior official to oversee program operations for the agency's employee benefits subdivision, according to a Monday update on the agency's online organization chart.
-
January 05, 2026
Trump Backs Biden's Medicare Drug Price Law At High Court
The Trump administration is defending the Biden-era Medicare Drug Price Negotiation program to the U.S. Supreme Court, asking the justices to deny AstraZeneca's petition challenging the program as unconstitutional.
-
January 05, 2026
Federal Workers Fight Gender-Affirming Coverage Rollback
A group of federal employees has filed a discrimination complaint with the U.S. Office of Personnel Management, saying the decision to end coverage for certain gender-affirming medical procedures under the workers' health insurance plans amounted to unlawful sex bias.
-
January 05, 2026
Thesis Supplements Illegally Sold As ADHD Drugs, Suit Says
A Louisiana woman is suing the owner of Thesis Nootropics in New York federal court, alleging that the company's line of supplements is illegally marketed as an alternative to Adderall and other medications despite lacking federal approval.
-
January 05, 2026
Paul Hastings Adds Hogan Lovells Duo To Life Sciences Team
Two longtime Hogan Lovells partners, including the head of its pharmaceutical and biotechnology regulatory practice, have joined Paul Hastings LLP in Washington, D.C., the firm announced Monday.
-
January 02, 2026
NC Hospital, Nurses Score Initial OK For $75K Meal Break Deal
A North Carolina hospital will pay $75,000 to end an overtime lawsuit alleging it automatically deducted meal breaks from nurses' pay, according to a federal judge's order initially approving the settlement.
-
January 02, 2026
IRS Floats Updates To Fee Paid By Brand Drugmakers
The Internal Revenue Service floated updates to regulations governing how branded prescription drug manufacturers or importers should calculate an annual fee established by the Affordable Care Act, a move the agency said aims to incorporate changes in drug discount programs and clarify tax reporting.
-
January 02, 2026
Bankruptcy And Restructuring Trends To Watch In 2026
Bankruptcy practitioners expect restructuring activity to remain elevated in the year ahead as more debt comes due and businesses continue to grapple with economic uncertainty. Major court rulings on bankruptcy plans, innovations in out-of-court debt deals and shifts in what is permitted under Chapter 11 will also have important effects in 2026, experts told Law360.
-
January 02, 2026
Drug Pricing Battles To Watch In 2026
With drugmakers already pushing back on drug affordability programs and policies, Law360 looks at the year ahead for litigation focused on state and federal drug pricing programs.
-
January 02, 2026
Approach The Bench: What Judges Had To Say In 2025
Jurists discussed their strategies for decision-making, the difficulties of case management, and their predictions for the future of litigation in a dozen interviews with Law360 this year.
-
January 02, 2026
5 Cases In Georgia To Keep An Eye On In 2026
Attorneys in Georgia will be watching several legal battles involving hot-button issues in the new year, including a suit over gender-affirming healthcare in state prisons, multidistrict litigation seeking to hold Meta and others liable for alleged social media addiction, and a bid by the U.S. Justice Department to obtain 2020 election records. Here is a look at five cases to follow in 2026.
-
January 02, 2026
Product Liability Cases To Watch In 2026
Trials in the massive litigation against social media giants like Facebook are set to start in the New Year, as litigants battle over whether the companies should be held responsible for allegedly designing their platforms to addict youth, causing a bevy of mental health harms, and cases against popular weight loss drugs like Ozempic continue to mount. Here's what else product liability attorneys will be watching in 2026.
-
January 02, 2026
5 Policy Areas Benefits Attys Should Keep Tabs On In 2026
The new year promises policy shifts that could change the legal landscape for health and retirement benefits, including action to follow through on an executive order encouraging alternative assets in 401(k) plans, and a potential replacement for a Biden-era rule covering how retirement plan managers can factor environmental and social issues into their investment strategy. Here are five policy areas benefits attorneys will be watching in 2026.
-
January 02, 2026
Trade Secret Trends To Watch In 2026
The landscape of trade secret law could see significant developments in 2026 as courts address the aftermath of astronomical jury awards and navigate jurisdictional tensions surrounding the timing and specifics of trade secret disclosures in litigation.
-
January 02, 2026
Merger Settlements Keep Rolling, With A Hitch
The U.S. Department of Justice and Federal Trade Commission took a more business friendly approach to merger reviews in 2025 than the previous administration, with a string of settlements allowing deals to move ahead without a challenge.
-
January 02, 2026
NC Legislation To Watch In 2026: Healthcare Funding In Focus
A spate of healthcare legislation is on the line as North Carolina lawmakers get ready to return to the General Assembly in January, from tenuous funding for Medicaid and Planned Parenthood to efforts to control the Tar Heel state's skyrocketing healthcare costs.
-
January 02, 2026
Marijuana And Hemp Policy Enters Uncharted Waters In 2026
The final weeks of 2025 produced two monumental shifts poised to reshape the cannabis policy landscape in the coming year: Congress' approval of language to redefine lawful hemp nationwide and a presidential executive order directing the administration to loosen federal restrictions on marijuana for the first time in over five decades.
-
January 02, 2026
California Cases To Watch In 2026
Legal experts following California courts in 2026 are tracking high-stakes personal injury, antitrust and copyright battles against giants in the social media, artificial intelligence and entertainment industries, as well as wide-ranging legal disputes arising from Los Angeles wildfires and high-profile appeals pending before the California Supreme Court.
-
January 02, 2026
Florida Cases To Watch In 2026
All eyes will be on the Eleventh Circuit in 2026 as it decides what to do with a Florida federal judge's decision determining that the qui tam provision of the False Claims Act is unconstitutional, but Florida appellate courts will also be grappling with the punitive damages framework in the state and the retroactive application of statutory amendments. Here, Law360 looks at cases attorneys in Florida will be watching in 2026.
Expert Analysis
-
Deference Ruling Could Close The FAR Loophole
A recent U.S. Court of Federal Claims decision may close a loophole in the Federal Acquisition Regulation that allows agencies to circumvent the Trade Agreements Act, significantly affecting federal pharmaceutical procurements and increasing protests related to certain Buy American Act waivers, say attorneys at Polsinelli.
-
Agentic AI Puts A New Twist On Attorney Ethics Obligations
As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG.
-
When AI Denies, Insurance Bad Faith Claims May Follow
Two recent rulings from Minnesota and Kentucky federal courts signal that past statements about claims-handling practices may leave insurers using artificial intelligence programs in claims administration vulnerable to suits alleging bad faith and unfair trade practices, say attorneys at Cozen O'Connor.
-
Health Insurance Kickback Cases Signal Greater Gov't Focus
A series of recent indictments by federal prosecutors in California suggests that the Eliminating Kickbacks in Recovery Act is gaining momentum as an enforcement tool against illegal inducement of patient referrals in the realm of commercial health insurance, say attorneys at BakerHostetler.
-
FDA Transparency Plans Raise Investor Disclosure Red Flags
The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter.
-
Series
Being A Professional Wrestler Makes Me A Better Lawyer
Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.
-
Series
Law School's Missed Lessons: Adapting To The Age Of AI
Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor.
-
Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning
A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.
-
DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech
The U.S. Department of Justice's recent False Claims Act settlement with Illumina over alleged cybersecurity deficiencies suggests that enforcement agencies and whistleblowers are focusing attention toward cybersecurity in life sciences and medical tech, but also reveals key unanswered questions about the legal viability of such allegations, say attorneys at Morgan Lewis.
-
Demystifying The Civil Procedure Rules Amendment Process
Every year, an advisory committee receives dozens of proposals to amend the Federal Rules of Civil Procedure, most of which are never adopted — but a few pointers can help maximize the likelihood that an amendment will be adopted, says Josh Gardner at DLA Piper.
-
With Obligor Ruling, Ohio Justices Calm Lending Waters
A recent decision by the Ohio Supreme Court, affirming a fundamental principle that lenders have no duty to disclose material risks to obligors, provides clarity for commercial lending practices in Ohio and beyond, and offers a reminder of the risks presented by guarantee arrangements, says Carrie Brosius at Vorys.
-
How 2nd Circ. Cannabis Ruling Upends NY Licensing
A recent Second Circuit decision in Variscite NY Four v. New York, holding that New York's extra-priority cannabis licensing preference for applicants with in-state marijuana convictions violates the dormant commerce clause, underscores that state-legal cannabis markets remain subject to the same constitutional constraints as other economic markets, say attorneys at Harris Beach.
-
Parenting Skills That Can Help Lawyers Thrive Professionally
As kids head back to school, the time is ripe for lawyers who are parents to consider how they can incorporate their parenting skills to build a deep, meaningful and sustainable legal practice, say attorneys at Alston & Bird.
-
Series
Teaching Trial Advocacy Makes Us Better Lawyers
Teaching trial advocacy skills to other lawyers makes us better litigators because it makes us question our default methods, connect to young attorneys with new perspectives and focus on the needs of the real people at the heart of every trial, say Reuben Guttman, Veronica Finkelstein and Joleen Youngers.
-
Federal AI Action Plan Marks A Shift For Health And Bio Fields
The Trump administration's recent artificial intelligence action plan significantly expands federal commitments across biomedical agencies, defining a pivotal moment for attorneys and others involved in research collaborations, managing regulatory compliance and AI-related intellectual property, says Mehrin Masud-Elias at Arnold & Porter.